Comparing Dydrogesterone and GnRH Agonists for IVF Outcomes
Comparison Between Effects of Dydrogesterone, Cetrorelix Acetate and Triptorelin on Intra Cytoplasmic Sperm Injection Outcomes
This study is testing whether a medication called Dydrogesterone works better than GnRH agonists in helping women undergoing IVF have healthier eggs and embryos.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 387 (estimated) |
| Ages | 20 Years to 40 Years |
| Sex | Female |
| Sponsor | Beni-Suef University Academic / other |
| Locations | 1 site (Banī Suwayf, Beni Suef) |
| Trial ID | NCT05972902 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to compare the effects of Dydrogesterone with GnRH agonist and antagonist protocols on preventing premature LH surge and improving the quality of oocytes and embryos in women undergoing intra-cytoplasmic sperm injection (ICSI). It is a randomized controlled trial involving 387 infertile women at Beni-Suef University Hospital, who will be divided into three groups based on the treatment protocol they receive. Participants will undergo thorough evaluations and assessments before being enrolled in the study, ensuring they meet specific inclusion and exclusion criteria.
Who should consider this trial
Good fit: Ideal candidates for this study are infertile women who are scheduled for ICSI and meet the inclusion criteria.
Not a fit: Patients with severe endometriosis, uterine malformations, or uncontrolled endocrinopathies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance IVF outcomes by improving oocyte and embryo quality, leading to higher pregnancy rates.
How similar studies have performed: Other studies have shown promising results with similar approaches in optimizing IVF protocols, suggesting potential for success in this trial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Having indications for ICSI. Exclusion Criteria: 1. Any known contraindications to the approved fertility drugs. 2. Severe endometriosis. 3. Uterine malformations or abnormal uterine cavity. 4. Uncontrolled endocrinopathies: DM, hyperthyroidism, hypothyroidism. 5. Severe male factor for infertility.
Where this trial is running
Banī Suwayf, Beni Suef
- Beni-suef university Hospital — Banī Suwayf, Beni Suef, Egypt (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.